![Mike Gutch](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mike Gutch
Direttore Finanziario/CFO presso
Entasis Therapeutics, Inc.
Profilo
Michael J.
Gutch is currently a Director at Southeast BIO, Albireo AB, Entasis Therapeutics Ltd., The Johns Hopkins University, and Alzheimers Drug Discovery Foundation.
He is also the Chief Financial & Business Officer at Entasis Therapeutics, Inc. since 2017.
Previously, he held positions as a Director at AstraZeneca PLC, PhaseBio Pharmaceuticals, Inc., BlinkBio, Inc., G1 Therapeutics, Inc., and Affinita Biotech, Inc. He was also an Investment Director at H.I.G.
Capital LLC from 2008 to 2011.
Additionally, he served as the CFO, Director & Chief Business Officer at Albireo Pharma, Inc. from 2015 to 2023.
He has also worked at Eli Lilly & Co., MedImmune Ventures, Inc., LV Management Group, LLC, H.I.G.
BioHealth Partners LLC, and H.I.G.
Ventures LLC.
Dr. Gutch holds a doctorate degree from Stony Brook University, an MBA from Indiana University, and an undergraduate degree from Alfred University.
Posizioni attive di Mike Gutch
| Società | Posizione | Inizio |
|---|---|---|
Southeast BIO | Direttore/Membro del Consiglio | - |
Alzheimers Drug Discovery Foundation
 Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology Operates as a research organisation | Corporate Officer/Principal | - |
The Johns Hopkins University
 The Johns Hopkins University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Albireo AB
 Albireo AB Pharmaceuticals: MajorHealth Technology Develops bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders | Direttore/Membro del Consiglio | - |
Entasis Therapeutics, Inc.
 Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for infectious diseases | Direttore Finanziario/CFO | 11/04/2017 |
Entasis Therapeutics Ltd.
 Entasis Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products | Direttore/Membro del Consiglio | 23/04/2018 |
Precedenti posizioni note di Mike Gutch
| Società | Posizione | Fine |
|---|---|---|
Noema Pharma AG
 Noema Pharma AG Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage biotech company that provide therapeutics for central nervous system | Direttore Finanziario/CFO | 08/01/2025 |
| ALBIREO PHARMA, INC. | Direttore Finanziario/CFO | - |
| ENTASIS THERAPEUTICS HOLDINGS INC. | Direttore Finanziario/CFO | 24/02/2022 |
| ░░░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Formazione di Mike Gutch
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
62
Relazioni di 1° grado
24
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 24 |
|---|---|
Eli Lilly & Co.
 Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
PhaseBio Pharmaceuticals, Inc.
 PhaseBio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of novel therapies for cardiovascular diseases | Health Technology |
MedImmune Ventures, Inc.
 MedImmune Ventures, Inc. Investment ManagersFinance MedImmune Ventures invests in private biotechnology companies located across the globe primarily in North America. The firm focuses on healthcare sectors such as molecules, vaccines, pharmaceutical technologies, medical devices, diagnostics, imaging and healthcare IT. The firm provides financing for seed, early, later and mezzanine stage capital requirements with an investment size ranging from USD 5 - USD 10 million per round. It acts as a lead investor and takes an active role on the board of directors. | Finance |
BlinkBio, Inc.
 BlinkBio, Inc. Pharmaceuticals: MajorHealth Technology Develops orally active drugs that act like small drug molecules | Health Technology |
H.I.G. Capital LLC
 H.I.G. Capital LLC Financial ConglomeratesFinance Operates as an alternative investment firm | Finance |
H.I.G. Ventures LLC
 H.I.G. Ventures LLC Investment ManagersFinance Functions as an alternative investment manager | Finance |
Stony Brook University
 Stony Brook University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LV Management Group, LLC
 LV Management Group, LLC Investment ManagersFinance Lilly Ventures invests in companies located in the European regions and North America, primarily in the United States. The firm target companies operating in the fields of life sciences, biotechnology, medical technology and healthcare information technology sectors. It provides financing for early stage capital requirements. | Finance |
Indiana University
 Indiana University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Johns Hopkins University
The Johns Hopkins University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alfred University
 Alfred University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Southeast BIO | |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology Operates as a research organisation | Health Technology |
Albireo Ltd.
 Albireo Ltd. Pharmaceuticals: MajorHealth Technology Develops therapies that address medical needs in the gastrointestinal and liver disease area | Health Technology |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Develops bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders | Health Technology |
H.I.G. BioHealth Partners LLC
 H.I.G. BioHealth Partners LLC Investment ManagersFinance H.I.G. BioHealth Partners invests in companies located in the United States. The firm targets companies operating in the field of medical devices, biopharmaceuticals, digital health, tool & diagnostics and product related services. It provides financing for acquisition, IPO and growth stage capital requirements in the form of equity and debt. It also makes follow on investments. | Finance |
G1 Therapeutics, Inc.
 G1 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for cancer treatment | Health Technology |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for infectious diseases | Health Technology |
Affinita Biotech, Inc.
 Affinita Biotech, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research and development of pharmaceuticals and biotechnology | Commercial Services |
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets novel bile acid modulators for liver and gastrointestinal diseases and disorders | Health Technology |
Entasis Therapeutics Holdings, Inc.
 Entasis Therapeutics Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical biopharmaceutical company that engages in development of antibacterial products | Commercial Services |
Entasis Therapeutics Ltd.
Entasis Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products | Health Technology |
Noema Pharma AG
Noema Pharma AG Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage biotech company that provide therapeutics for central nervous system | Commercial Services |
